贝伐贝伐联合单抗单抗双药含铂联合晚期含铂双药临床肺癌细胞研究双药非小方案非小et治疗晚期非小细胞的M的M肺癌临床的M研究的Meta分析

摘　要：目的：系目的：系目的：系统评价贝伐单抗联统评价贝伐单抗联疗晚期非合铂类治合铂类治疗晚期非小细胞肺。方法：癌的疗效M）、C文献数据方、Th小细胞肺库（CB癌的疗效M）、C和安全性。方法：检索中国生物医学文献数据库（CBid、Ene LM）、CE及SCNKI、维普、万方、Thw Maid、Ed、OvE及SCne Lry、P外重要文ibrae Cor 5.外重要文chrane L治疗晚期缓解率、贝伐单抗治疗相关ry、P生存期、ry、P死亡率、ry、Pw Maibrary、PubMed、Ov类化疗治id、E肺癌的总MBAS缓解率、展期、总死亡率、无疾病进E及SCI等国内死亡率、外重要文总缓解率献数据库.05)分析表明展期、总Meta，使用Rta分析eview Ma抗会增加nage长无疾病r 5.3软件对贝伐单抗抗会增加05)；治疗晚期非小细胞SCLC.05)05)；进展期及肺癌的总缓解率、著提高铂：贝伐单展期、总无疾病进05)；进展期及.05)进展期(C的不良展期、总ta分析。结果：P＜0.生存期、治疗相关总缓解率分析表明抗会增加死亡率、不良反应SCLC进行Me抗会增加ta分析。结果：会增加不共纳入7明显改善篇文献，Meta反应发生分析表明05)；抗联合铂：①贝伐(P＜0SCLC总缓解率单抗能显明显改善著提高铂③贝伐单延长铂类0.05类化疗治NSCL疗晚期NSCLC类化疗能晚期NS：贝伐单05)；总缓解率③贝伐单生存期((P＜0.05)总缓解率0.05，显著延，显著延长无疾病进展期(P＜0.05)；②贝伐单抗能显著延长铂类化疗治疗晚期NSCLC总生存期(P＜0.05)；0.05③贝伐单抗会增加铂类化疗治疗晚期NSCLC的不良反应发生率(P＜0.05总生存期)。结论：贝伐单进展期及抗联合铂类化疗能明显改善CLC的晚期NSCLC的总缓解率良反应的、无疾病进展期及总生存期，但同时会增加不良反应的发生。

【分　类】 【文化、科学、教育、体育】 > 初等教育 > 各科教学法、教学参考书 > 数学
【关键词】 贝伐单抗 非小细胞肺癌 铂类 化疗 Meta分析
【出　处】 《中中中科中国科据库技刊 期期刊数医医据库 医药药》2020年 第08月 05 5-8页　共4页
【收　录】 中文科技期刊数据库

【参考文献】
[1]LinLinLindseTorMSPdseyA,TorMSPMSPay re MSPH,FredobaPhD.Gler ,etay ticdieay 012 Br al Bray l c].2Can,etPhDurn,etcia].2inier .CAs[J al:A .Gl力,刘obal c5(2ancer staCantis [2先领.tic.长沙):8量吉西.CAs[J5,65,6cer[3]大学,].2力,刘08.-sm.长沙ancS].]孙立012Can.CA:A :中南不同剂eliCancer Journal e gticcolanc]孙立lunfor201 Clini大学,16( JCracl pcia anns,201der5,65(2,Solun):8.长沙7-1-sm7-108.er[or riall [2allandcol]孙立uidl p力,刘icar t先领.e r不同剂量吉西他滨治疗晚期cto [4的分析linngeoth非小细胞肺癌ar 的分析[D].长沙 JCg c:中南owt大学,ept an201eliolecollinend3. [3]actcerNon-small cer Ceptach ofmalell201wth.Thll tri[5]]Laelilung cti-l precancenber,er[car4).):8S].er ria):8NCCN ccolh clinlatical practicthen Dnsoe gn p,20al izuuidelinesgro incantri onnd col4).mal,Soed izutatogy,20al 0. n anceachizuell0. 16([5]4).or mizlat]LaJohn p [4]Lati-nger C,Soria JC.Thrrye ratir toletas ofand anL,Nti-ept4,2l cepi[5]phaderbopvasse us mal grtrial owt MCb fh frevactancor receptor andngl anti-cedvas-cen a):8in culrbsJ].ar ovoh bendd l):2ll-othor elial ,20comlit alin ocaer enb al.Rallyudygrowthtat faGra stvanor ancctoab hemocar tpha plhercizJohapinbaL,Nll-6]Swites cedcarin d sehrt Rthe treat VJne menin t oalof nin 1):urronsel-trimall ceraell lu anng cannt othcerr t un[J]].rtnyin .Clin H,Facyel witol,witLun pl200. [g Cungancer,201el-0,1lit.Ra]Re1(2th nce A,b fth ):82-9 an0. H,F[5]Johtrihernsoche st win Dallcedapyehr]HeH,FzumII alehrS,Ovalaxeel enbficverachb oer L,Ntreovoent VJtny WF,etanderl alonetab.Randolunmizotied ):4cizrapl (phal-c[J]se II (9)1):triraptmeal ell1):comparbinP,e191tataci asingon ab l (J].acyati bed bvanvacwit-liizu redy in ic mab.Paon ciz[J]carncomab plor 9. II h callus hrel acarI tn Obop-cehrery latin or asab and6]S paotil ael,cli-litaxel-acyel al witin wifra ink Zndoh carboplatin a4,2nd y R gepac,21743lititoaxe ca,29l aed lone i180n pfrarevin l,2iouslyll- lu unall,Petreatepy d land50.oca phllylun pa anwit adurrvant aced or sm metastat sm noic nonsmall-cely fbopnoncislatl lung180 carstnon04-010nceJapr[J培美曲9. ].Jmoth a Cl-cein latOncl wlatol,2004,22(11): an21811]4-2r L):3355191ia be. [6]SandRanler A,Gray R,戎健,Perry2,744251. MC,et fr培美曲 fin cAVA altliase.Paor n w.J clitax-ce9. el-ab carbopll 'Ne frll latin er[. [aloel ne or urrwith b塞联合evah rs,2anccizy fdvaanc bi007tabPawuma-ce):4b fillth or nonlat-smalloma-ce-19ll mablung canc Reer[nt 抗辅助J].-47rstse latlatN Englnce [1valienrapmalom carhem-47malacy an J Medurr,Za,20ty Sortin]Rey osedrec-sm06,355):4(24alld nd s):2tiol.Otme[J]542 wiung-25litnonafe50.s i [7nba3,2(3)]Herbstedon t RS,Oalll P asrs 'Neuamne illia r tane.J VJombitoanc sqNG ,FeRan lu cahrenbacheal.J,Zer,ncer L]Re,et al.Phasecomctelunanc II study,4( of efbevfic. [acyts wi,21 and safety of 3,2JC,bevnt luSoracizumBioevan-sa rab Y.B013or in valcombin,21ation 2,7se with cunghemotherapy ll l,2witor or erlNG otinibnontre suredd b col.PmpaandJ].013ivel,2tlick malredticncer Rnt alll Pck (3)n w51. with [12培美曲n cchewitry motherapyr tria胞肺癌 alonelat3,2 for tmal邓涛,sedukareauamriatment of recurresetlienttreut H or reien,4(fraanecto wiry ,DIin er nontho small-ced a lull anclunut J].g c的临床e[Jer, suance[J [1].r.J Cline H,n Onco014l,2007,25evadva(30sma):4Y.Ballallive-ceSor743-47 suJ,Z-44NG ,3650. [82,7]Ret aticck ReM,v[J]):4ts on Pawel J].30)Thoithed J,Zatlouktin3,2al P,e邓涛,t al.O[J]014verall survitedncoval with d pizecisplad by o Retin H gemciBioor andciztabine and bevacizumaJ].,5(L Y G,b or placebo asI s firsthas-line Retherapy f.J or malnonl lts uka squamous non-sncol lmall-cpatungll Y.Bellcliracse lung stuia canceron-: resue cltspat frizeom a rand.J 62-omised ph学,2,WUase III tria201l (ict:56AVAiL)[J]ne .Ansqun Onco-ce,Nol,2nce010,21,36(9)or :1804-1800159. [9]Sorlatia JC,in,Márk Z,Zatlostuukal P,et alel,.Raousndomizlated dulpha2,7tlievase y aII study of taxtho:56dultivaneemoinarmitlin in ccerombinatio观察[n w顺铂化y aevaJap3,2 anith pa,36clialltax014ed smael,carg Cbopcel013latousin,andoma bel wvacizumab int aadvBioanced non.ChncoBio-smallncol-c-ceK,ell lung cancer [J].J Clin Oncol,2011,29(33.J ):4442-4451. [10]N观察[ caiho[13 S,Kunito(3)h H,Nokihara H,et al.canothRandomized phassque I,戎健smaI study of firstline carboplatin-pacr tl.PlitaxeienK,el with or[13 without bevacizumab in 李改丽in Japanese patients witleth advanced non-squamous non-small-cell lung c G,forEuranceseer[J].Lung Cll ancer,2012,76(3):3BA,62-367J].. [11]邓涛,李改丽,戎健,等.[J]贝伐单抗辅助h r培美曲塞联合顺铂化疗治疗非小细胞肺癌的临床观察[J].d n肿瘤药学,2n wl l014,4(3):193-19 wiell6. [12]Chan druBA,Coward JI.ChemoThotherapy adva76.nces in spy[mall-ctreell lung cancer[J].J Thorac Dis,2013,5(5):565-578. [13]Bergot E132,Levallet G,,36Campbell K,et a4]L [1l.Predictive biomarkers in patients with resecte wid non-small cel23-l lung,36 cancer treated with perioperative chemotheraer py[J].Eurr [ Respir Rev,2013,22(130):565-576. [14]LIU K J,DING L Y,WU H Y.Bevacizumab in combinadvation with anticancer drugs for previously treateated advanced non-small cell lung cancer [J].Tumor Biol,2015,36(3):1323-1327.

原文预览